FindTrial
Sign In

Randomized Multicentric Proof-of-Concept Phase 2 Trial Doravirine in the Early Outpatient Management of West Nile Virus Infection in Patients at Risk of Progression - DORICO Trial

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-521677-14-00
Acronym
DORICO
Enrollment
50
Registered
2025-10-24
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

West Nile Virus Infection

Brief summary

To evaluate the percentage of patients in whom early treatment with Doravirine (DOR), administered to outpatients with West Nile Virus (WNV) infection and risk factors for progression, accelerates the 4-fold decline in viremia compared to the standard of care (SOC)

Detailed description

To evaluate the percentage of patients in whom early treatment with DOR, administered to outpatients with WNV infection and risk factors for progression, expedites the resolution of fever compared to SOC.

Interventions

DRUGPifeltro 100 mg film-coated tablets

Sponsors

Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
To evaluate the percentage of patients in whom early treatment with Doravirine (DOR), administered to outpatients with West Nile Virus (WNV) infection and risk factors for progression, accelerates the 4-fold decline in viremia compared to the standard of care (SOC)—

Secondary

MeasureTime frame
To evaluate the percentage of patients in whom early treatment with DOR, administered to outpatients with WNV infection and risk factors for progression, expedites the resolution of fever compared to SOC.—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026